Related Experiment Videos
[Nimesil effectiveness in rheumatoid arthritis].
Klinicheskaia Meditsina
|July 26, 2002
Summary
Nimesil demonstrated high clinical efficiency and good tolerance in patients with rheumatoid arthritis over a 12-week trial. The drug significantly improved articular syndrome with reversible side effects in most participants.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Context:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and pain.
- Effective and safe treatment options for RA are crucial for improving patient quality of life.
Purpose:
- To evaluate the clinical efficiency and safety of Nimesil in patients diagnosed with rheumatoid arthritis.
- To assess the impact of Nimesil on articular syndrome and overall patient well-being.
Summary:
- A multicenter open clinical trial involved 52 patients with verified rheumatoid arthritis.
- Nimesil was administered for 12 weeks at a daily dose of 200-400 mg, alongside basic therapy.
- Significant positive responses in articular syndrome were observed, with marked improvement in 23.4% and improvement in 79.2% of patients.
Impact:
- Nimesil showed high efficacy in managing rheumatoid arthritis symptoms, particularly the articular syndrome.
- The drug exhibited good tolerance, with reversible side effects reported in 15.3% of patients.
- These findings support Nimesil as a potentially valuable therapeutic option for rheumatoid arthritis management.